"PC-3人前列腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

傳代比例：1:2-1:4(首次傳代建議1:2)

生長特性：貼壁生長

細(xì)胞系的選擇需要考慮到細(xì)胞系的功能特點(diǎn)、生長速率、鋪板效率、生長條件和生長特征、克隆效率、培養(yǎng)方式等因素，如果您想高產(chǎn)量表達(dá)重組蛋白，您可以選擇可以懸浮生長的快速生長細(xì)胞系。細(xì)胞培養(yǎng)的操作步驟主要包括傳代、換液、凍存和復(fù)蘇。這些步驟確保了細(xì)胞能夠在實(shí)驗(yàn)室環(huán)境中長期存活并繼續(xù)增殖。傳代是將細(xì)胞從一個(gè)容器轉(zhuǎn)移到另一個(gè)容器的過程，以擴(kuò)大細(xì)胞數(shù)量；換液是為了清除代謝廢物并補(bǔ)充新鮮培養(yǎng)基；凍存則是為了長期保存細(xì)胞，而復(fù)蘇則是重新激活冷凍保存的細(xì)胞使其恢復(fù)正常生長。

換液周期：每周2-3次

TK10 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代；２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：KY70細(xì)胞、SK HEP-1細(xì)胞、NCI-H1651細(xì)胞

U-CH1 Cells;背景說明：骶骨脊索瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：CAL33細(xì)胞、Rin-M-5F細(xì)胞、CT26WT細(xì)胞

Statens Seruminstitut Rabbit Cornea Cells;背景說明：角膜；上皮 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SUDHL4細(xì)胞、HT細(xì)胞、HCEC-B4G12細(xì)胞

PC-3人前列腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

背景信息：PC-３源于一位６２歲白人男性IV級前列腺腺癌患者的骨轉(zhuǎn)移灶；有低水平的性酶活性和５-α-睪酮還原酶活性。

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

公司細(xì)胞系主要引進(jìn)ATCC、DSMZ、JCRB、KCLB、RIKEN、ECACC等細(xì)胞庫，細(xì)胞系體外培養(yǎng)，它們會(huì)成長為單層細(xì)胞，附著或緊貼在培養(yǎng)瓶上，或懸浮在體外的溶液中，細(xì)胞系復(fù)蘇周期短，公司細(xì)胞系狀態(tài)良好，飽滿，有光澤等優(yōu)點(diǎn)。EDTA的作用：許多人不用胰酶，只用EDTA，或者用胰酶/EDTA聯(lián)合作用。這里要明白，胰酶切割細(xì)胞外基質(zhì)的一些負(fù)責(zé)粘連和附著的蛋白，而EDTA通過螯合Ca離子，作用于整聯(lián)蛋白的活性，所以EDTA的作用更加溫和。有的人在胰酶里添加一些EDTA，或者對付特別難消化的細(xì)胞，添加多一些EDTA，就是這個(gè)道理。一般不要試圖延長消化時(shí)間(如果10min還消化不下來的話)，而應(yīng)該想其它辦法。

產(chǎn)品包裝：復(fù)蘇發(fā)貨：T25培養(yǎng)瓶(一瓶)或凍存發(fā)貨：1ml凍存管(兩支)

來源說明：細(xì)胞主要來源ATCC、ECACC、DSMZ、RIKEN等細(xì)胞庫

PC-3人前列腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

物種來源：人源、鼠源等其它物種來源

T241 Cells;背景說明：纖維肉瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：JeKo 1細(xì)胞、VMCUB1細(xì)胞、MRC5細(xì)胞

Hep G2/C3A Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３—１：６傳代，每周換液２次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HeLa-229細(xì)胞、GM05887細(xì)胞、SK-MEL28細(xì)胞

F56 [Human neoplasm] Cells;背景說明：F５６是一株人的腺癌細(xì)胞系，可用于腺癌發(fā)生機(jī)制的研究，也可用于抗癌藥物的篩選。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：CL-11細(xì)胞、PANC-02-03細(xì)胞、TE-85 clone 5細(xì)胞

Be Wo Cells;背景說明：取自人絨癌腦轉(zhuǎn)移組織，在倉鼠頰囊移植傳代８年。利用移植瘤組織進(jìn)行體外培養(yǎng)，建立細(xì)胞系。利用不同傳代方法建立了不同亞系，JEG-３是其衍生克隆。該細(xì)胞可以產(chǎn)生雌激素、孕激素、雌酮、雌二醇、雌三醇、hCG、胎盤催乳素、角蛋白。;傳代方法：１：３傳代，３-４天換液一次;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MDAMB330細(xì)胞、LNCaP C4-2B細(xì)胞、IMR-32細(xì)胞

┈訂┈購(技術(shù)服務(wù))┈熱┈線：1┈3┈6┈4┈1┈9┈3┈0┈7┈9┈1【微信同號】┈Q┈Q：3┈1┈8┈0┈8┈0┈7┈3┈2┈4；

形態(tài)特性：上皮細(xì)胞樣

細(xì)胞株(系)的使用，為醫(yī)學(xué)研究和測試工作帶來了大的方便。但細(xì)胞的傳代是有限制的，長期連續(xù)傳代的細(xì)胞，不僅消耗大量的人力和物力，而且細(xì)胞的生長與形態(tài)等會(huì)有一定退變或轉(zhuǎn)化，因而細(xì)胞失去原有的遺傳性，有時(shí)還會(huì)由于細(xì)胞污染而造成傳代中斷，種子丟失。因此，在實(shí)際工作中常需凍存一定數(shù)量的細(xì)胞，以備替換使用。細(xì)胞冷凍與復(fù)蘇是細(xì)胞培養(yǎng) 室的常規(guī)工作和通用技術(shù)。目前，細(xì)胞凍存Zui常用的技術(shù)是冷凍保存法，主要采用加適量保護(hù)劑的緩慢冷凍法凍存細(xì)胞。細(xì)胞在不加任何保護(hù)劑的情況下直接冷凍，細(xì)胞內(nèi)外的水分會(huì)很快形成冰晶，從而引起一系列不良反應(yīng)。如細(xì)胞脫水使局部電解質(zhì)濃度增GAO，pH值改變，部分蛋白質(zhì)由于上述原因而變性，引起細(xì)胞內(nèi)部空間結(jié)構(gòu)紊亂，溶酶體膜由此遭到損傷而釋放出溶酶體酶，使細(xì)胞內(nèi)結(jié)構(gòu)成分造成破壞，線粒體腫脹，功能丟失，并造成能量代謝障礙。胞膜上的類脂蛋白復(fù)合體也易破壞引起細(xì)胞膜通透性的改變，使細(xì)胞內(nèi)容物丟失。如果細(xì)胞內(nèi)冰晶形成較多，隨冷凍溫度的降低，冰晶體積膨脹造成細(xì)胞核DNA空間構(gòu)型發(fā)生不可逆的損傷，而致細(xì)胞死亡。因此，細(xì)胞冷凍技術(shù)的關(guān)鍵是盡可能地減少細(xì)胞內(nèi)水分，減少細(xì)胞內(nèi)冰晶的形成。采用甘油或二甲基亞砜作保護(hù)劑，這兩種物質(zhì)分子量小，溶解度大，易穿透細(xì)胞，可以使冰點(diǎn)下降，提GAO細(xì)胞膜對水的通透性，且對細(xì)胞無明顯毒性。慢速冷凍方法又可使細(xì)胞內(nèi)的水分滲出細(xì)胞外，減少胞內(nèi)形成冰結(jié)晶的機(jī)會(huì)，從而減少冰晶對細(xì)胞的損傷。

SUDHL16 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NK92-MI細(xì)胞、ARO81-1細(xì)胞、NCIH146細(xì)胞

LS 174T Cells;背景說明：LS １７４T是LS １８０ (ATCC CL １８７)結(jié)腸腺癌細(xì)胞株的胰蛋白酶化變種。 它比親本更易傳代，象LS １８０一樣生成大量的癌胚抗原(CEA)。 電鏡研究表明有豐富的微絲和細(xì)胞質(zhì)粘液素液泡。 直腸抗原３陽性。 p５３抗原表達(dá)陰性，但mRNA表達(dá)陽性。 與ATCC CL-１８７來源于同一個(gè)腫瘤。LS １７４T細(xì)胞角蛋白染色陽性。 癌基因c-myc, N-myc, H-ras, N-ras, Myb, 和 fos的表達(dá)呈陽性。 癌基因k-ras和sis的表達(dá)未做檢測。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HS 445T細(xì)胞、P3-NS1/1-Ag4-1細(xì)胞、L 540細(xì)胞

KMM1 Cells;背景說明：骨髓瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RMS1598細(xì)胞、SACCLM細(xì)胞、Hs-578T細(xì)胞

3T6-Swiss albino Cells;背景說明：胚胎；成纖維；自發(fā)永生；雄性；Swiss albino;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PC-9/S1細(xì)胞、STC-1細(xì)胞、G361細(xì)胞

Tu 177 Cells;背景說明：喉鱗癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：KP-4細(xì)胞、NCI-SNU-1細(xì)胞、H-82細(xì)胞

LA-795 Cells;背景說明：肺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NR 8383細(xì)胞、HTori 3細(xì)胞、DHL6細(xì)胞

MV4II Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Asian Medical Center-Head and Neck cancer-8細(xì)胞、KYSE520細(xì)胞、HFLS-RA細(xì)胞

CEM-T4 Cells;背景說明：急性T淋巴細(xì)胞白血??；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-MB 468細(xì)胞、OCI-AML-2細(xì)胞、MDCK (NBL-2)細(xì)胞

HCA-7 Cells;背景說明：結(jié)腸腺癌；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：VP267細(xì)胞、Hep G2-Luc細(xì)胞、PBL細(xì)胞

253J Cells;背景說明：膀胱癌；淋巴結(jié)轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：GM3569細(xì)胞、Mouse Podocyte Clone-5細(xì)胞、RT4P細(xì)胞

NCI-H929 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：保持細(xì)胞密度在５×１０５—１×１０６ cells/ml之間，每周換液２—３次;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：S3-HeLa細(xì)胞、Glioma 261細(xì)胞、NCI-H865細(xì)胞

LMH Cells;背景說明：肝癌；雄性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SAOS 2細(xì)胞、Madin-Darby Canine Kidney細(xì)胞、NCI-H920細(xì)胞

C3H10T1/2CL8 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SKNFI細(xì)胞、TE-15細(xì)胞、H-2073細(xì)胞

KBM-5 Cells;背景說明：慢性髓白血?。慌?傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：BPH-1細(xì)胞、University of Michigan-Urothelial Carcinoma-1細(xì)胞、Oregon J-111細(xì)胞

AML193 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代。３天內(nèi)可長滿。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：NCIH146細(xì)胞、MOLP2細(xì)胞、GM01232E細(xì)胞

P-388D1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OV1063細(xì)胞、L-Wnt3A細(xì)胞、Neuro 2a細(xì)胞

PFSK1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：DC 2.4細(xì)胞、Hs-274-T細(xì)胞、TK 10細(xì)胞

Abcam A-549 GZMB KO Cells(提供STR鑒定圖譜)

Abcam THP-1 SETD2 KO Cells(提供STR鑒定圖譜)

BayGenomics ES cell line CSD301 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line RRT059 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YTC251 Cells(提供STR鑒定圖譜)

ChiPSC20 Cells(提供STR鑒定圖譜)

DA02175 Cells(提供STR鑒定圖譜)

DRICUi040-A Cells(提供STR鑒定圖譜)

GM03759 Cells(提供STR鑒定圖譜)

TW01 Cells;背景說明：鼻咽癌;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：WEHI3B細(xì)胞、CCD966SK細(xì)胞、SKRC-39細(xì)胞

PC-3人前列腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

HCC2935 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：６傳代，每周２-３次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：GLC82細(xì)胞、L5178Y TK+/-3.7.2c細(xì)胞、OC-3-VGH細(xì)胞

SKUT1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：４-１：１２傳代，２天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：Tn5 B1-4細(xì)胞、Calf Pulmonary Artery Endothelial細(xì)胞、HepG2細(xì)胞

CCRF/CEM Cells;背景說明：G.E. Foley 等人建立了類淋巴母細(xì)胞細(xì)胞株CCRF-CEM。 細(xì)胞是１９６４年１１月從一位四歲白人女性急性淋巴細(xì)胞白血病患者的外周血白血球衣中得到。此細(xì)胞系從香港收集而來。;傳代方法：１：２傳代。３天內(nèi)可長滿。;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：M-1細(xì)胞、PL 5細(xì)胞、DHBE細(xì)胞

NE-4C Cells;背景說明：神經(jīng)干 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：PK-136細(xì)胞、rRMECs細(xì)胞、NuTu-19細(xì)胞

NCIH1048 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：８傳代；;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：SW-1573細(xì)胞、OCIAML5細(xì)胞、MDCC-MSB1細(xì)胞

6B12 Cells(提供STR鑒定圖譜)

PFSK Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI H548細(xì)胞、RAW264細(xì)胞、SUSM-1細(xì)胞

J 82 Cells;背景說明：電子顯微鏡下未觀察到橋粒但觀察到數(shù)目不同的粗面內(nèi)質(zhì)網(wǎng)和突出微絲。 含ras (H-ras)癌基因。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：RK-13細(xì)胞、MNNG-HOS (TE 85, clone F-5)細(xì)胞、REC細(xì)胞

M-NFS-60 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：ACC-2細(xì)胞、EOL1細(xì)胞、Caco-2 BBe細(xì)胞

NCI-H2195 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Menschliche Und Tierische Zellkulture-3細(xì)胞、HEK 293 EBNA細(xì)胞、VMCUB1細(xì)胞

SHSY-5Y Cells;背景說明：據(jù)報(bào)道，該細(xì)胞的密度可高達(dá)１×１０６cells/cm２，具有中等水平的多巴胺β羥化酶的活性。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：HEL-1細(xì)胞、SKLMS-1細(xì)胞、Human Corneal Epithelial cells-Transformed細(xì)胞

LoMeT-ccRcc Cells;背景說明：腎透明細(xì)胞癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RASMCs細(xì)胞、EoL-1細(xì)胞、OVCAR.5細(xì)胞

TE1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：消化３-５分鐘。１：２。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：H-2228細(xì)胞、COLO-320HSR細(xì)胞、Med 341細(xì)胞

H-2052 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：SUM149-PT細(xì)胞、SCL II細(xì)胞、Hs 863.T細(xì)胞

GM10640 Cells(提供STR鑒定圖譜)

HAP1 CD63 (-) Cells(提供STR鑒定圖譜)

RASMC Cells;背景說明：主動(dòng)脈；平滑肌 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：OCI-Ly8細(xì)胞、TPC-1細(xì)胞、WSU-DLCL-2細(xì)胞

CT26.CL25 Cells;背景說明：結(jié)腸癌； BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MDA-435細(xì)胞、H-64細(xì)胞、H2122細(xì)胞

MD Anderson-Metastatic Breast-175-VIII Cells;背景說明：該細(xì)胞源自一位５４歲患有乳腺導(dǎo)管癌白人女性的胸腔積液。;傳代方法：１：２—１：６傳代，每周換液２—３次;生長特性：松散貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：LM TK negative細(xì)胞、MDAMB175細(xì)胞、OVCAR 5細(xì)胞

MLTC-1 Cells;背景說明：睪丸間質(zhì)瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MV3細(xì)胞、HemECs細(xì)胞、SK N SH細(xì)胞

MC3T3, E1 subgroup-4 clone Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Ketr-3細(xì)胞、HAPI細(xì)胞、C-6細(xì)胞

COLO-829 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代，２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：A-10細(xì)胞、SW48細(xì)胞、CA 46細(xì)胞

Ly10 Cells;背景說明：彌漫大B細(xì)胞淋巴瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK-LU-1細(xì)胞、NRK 52E細(xì)胞、HT 144細(xì)胞

BEL 7405 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：NCI-H128細(xì)胞、D-341細(xì)胞、IOSE80UBC細(xì)胞

HG03894 Cells(提供STR鑒定圖譜)

ILT-My Cells(提供STR鑒定圖譜)

LTC-7 Cells(提供STR鑒定圖譜)

ND01408 Cells(提供STR鑒定圖譜)

PCA-5 Cells(提供STR鑒定圖譜)

Ubigene A-549 ADAM17 KO Cells(提供STR鑒定圖譜)

UNEWi025-B Cells(提供STR鑒定圖譜)

HEV0110 Cells(提供STR鑒定圖譜)

U343 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長　;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HEK AD293細(xì)胞、FO [Mouse myeloma]細(xì)胞、SKNBE(2)細(xì)胞

TK+/- (clone 3.7.2C) Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：NCI-H2106細(xì)胞、130 T細(xì)胞、PLC-8024細(xì)胞

JHH-2 Cells;背景說明：肝癌；腹水轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MRC-9細(xì)胞、LP1細(xì)胞、IM95細(xì)胞

U 138 MG Cells;背景說明：星形細(xì)胞瘤；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：A375-MEL細(xì)胞、R-1059-D細(xì)胞、32D-Cl3細(xì)胞

451-LU Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U-138 MG細(xì)胞、LY-R細(xì)胞、HOP92細(xì)胞

451-LU Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：U-138 MG細(xì)胞、LY-R細(xì)胞、HOP92細(xì)胞

TK 10 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：３-１：６傳代；２-３天換液１次。;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：MC-116細(xì)胞、AG06814-N細(xì)胞、CAL851細(xì)胞

H64 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：EC109細(xì)胞、NCI H82細(xì)胞、PLC PRF 5細(xì)胞

NCI H226 Cells;背景說明：１９８０年分離建立。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞樣;相關(guān)產(chǎn)品有：Human Microvascular Endothelial Cell line-1細(xì)胞、HCC78細(xì)胞、BAR-T細(xì)胞

Ha Fe Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HCC1008細(xì)胞、AN3CA細(xì)胞、OVCAR.8細(xì)胞

3T3L1 Cells;背景說明：３T３-L１是從３T３細(xì)胞（Swissalbino）中經(jīng)克隆分離得到的連續(xù)傳代的亞系。該細(xì)胞從快速分裂到匯合和接觸性抑制狀態(tài)經(jīng)歷了前脂肪細(xì)胞到脂肪樣細(xì)胞的轉(zhuǎn)變。該細(xì)胞鼠痘病毒陰性；可產(chǎn)生甘油三酯，高濃度血清可增強(qiáng)細(xì)胞內(nèi)脂肪堆積。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞樣;相關(guān)產(chǎn)品有：CATHa細(xì)胞、RKOAS451細(xì)胞、HCC-2185細(xì)胞

3T3J2 Cells;背景說明：胚胎；成纖維 Cells;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：UMRC2細(xì)胞、CAL-39細(xì)胞、HEK-293-FT細(xì)胞

WM-2664 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Mahlavu細(xì)胞、SNUC2B細(xì)胞、MDCK supertube細(xì)胞

8305C_1 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：６傳代;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：NCI-H2087細(xì)胞、P-815細(xì)胞、H345細(xì)胞

OCILY10 Cells;背景說明：彌漫大B細(xì)胞淋巴瘤;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：HLF-a細(xì)胞、RSMC細(xì)胞、C3H10T1/2 clone8細(xì)胞

SCRP2208i Cells(提供STR鑒定圖譜)

AMO1 Cells;背景說明：漿細(xì)胞骨髓瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：半貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：RKO-AS-45-1細(xì)胞、MHCC 97-L細(xì)胞、OPM2細(xì)胞

SKMES Cells;背景說明：源于一位６５歲患有肺鱗狀細(xì)胞癌的白人男性，自轉(zhuǎn)移性胸腔積液分離而來。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：THLE2細(xì)胞、HcerEpic細(xì)胞、hFOB1.19細(xì)胞

Liver-02 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MC-4細(xì)胞、GM00637F細(xì)胞、Ca-Ski細(xì)胞

PC-3M IE8 Cells;背景說明：前列腺癌；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Vertebral Cancer of the Prostate細(xì)胞、MRC-V細(xì)胞、AML-12細(xì)胞

SK-BR-3 Cells;背景說明：這株細(xì)胞源自胸水。沒有病毒顆粒。亞顯微結(jié)構(gòu)特征包括微絲和橋粒，肝糖原顆粒，大溶酶體，成束的細(xì)胞質(zhì)纖絲。SK-BR-３細(xì)胞株過表達(dá)HER２/c-erb-２基因產(chǎn)物。;傳代方法：消化３-５分鐘，１：２,３天內(nèi)可長滿;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：KMS11細(xì)胞、CAMA-1細(xì)胞、OVCAR 432細(xì)胞

LNCaP C4-2 Cells;背景說明：前列腺癌；左鎖骨上淋巴結(jié)轉(zhuǎn)移；男性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SW480E細(xì)胞、DI TNC-1細(xì)胞、NK92細(xì)胞

PC-3人前列腺癌細(xì)胞代次低|培養(yǎng)基|送STR圖譜

A-172 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁或懸浮，詳見產(chǎn)品說明書部分;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：SK Mel 2細(xì)胞、HPAF-2細(xì)胞、KALS-1細(xì)胞

T-ALL 1 Cells;背景說明：該細(xì)胞源于一名復(fù)發(fā)T-ALL（急性T淋巴細(xì)胞性白血?。┑膬和耐庵苎痪哂泻軓?qiáng)的細(xì)胞毒性，體內(nèi)體外實(shí)驗(yàn)中都能破壞腫瘤細(xì)胞；IL-２可使細(xì)胞更好地生長；α/β TCR陽性，γ/δ TCR陰性；可產(chǎn)生IFNγ、TNF-α和GM-CSF。;傳代方法：維持細(xì)胞密度在４×１０５-１×１０６ cells/ml之間，２-３天換液１次　;生長特性：懸浮生長;形態(tài)特性：淋巴母細(xì)胞;相關(guān)產(chǎn)品有：ZR75-30細(xì)胞、NUGC-3細(xì)胞、OCI-Ly 19細(xì)胞

Japanese Tissue Culture-28 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：２傳代。３天內(nèi)可長滿。;生長特性：貼壁生長;形態(tài)特性：上皮細(xì)胞;相關(guān)產(chǎn)品有：HuH-28細(xì)胞、Pa18C細(xì)胞、Molm14細(xì)胞

RL-95-2 Cells;背景說明：這些細(xì)胞有α角蛋白，定義明確的連接復(fù)合體，張力絲和表面微絨毛。;傳代方法：１：２傳代;生長特性：貼壁生長;形態(tài)特性：上皮樣;相關(guān)產(chǎn)品有：SK-ES-1細(xì)胞、Hs 606.T細(xì)胞、UMNSAH-DF 1細(xì)胞

BALB 3T3 clone A31 Cells;背景說明：胚胎；成纖維；自發(fā)永生；雄性；BALB/c;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：貼壁;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：MG-63細(xì)胞、He-La細(xì)胞、H184A1細(xì)胞

SNT-8 Cells;背景說明：NK/T細(xì)胞淋巴瘤；女性;傳代方法：１：２-１：３傳代；每周換液２-３次。;生長特性：懸浮;形態(tài)特性：詳見產(chǎn)品說明書;相關(guān)產(chǎn)品有：Vero E-6細(xì)胞、EB3 [Human Burkitt lymphoma]細(xì)胞、H-9細(xì)胞

C-Lu65 Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：１：１０傳代;生長特性：貼壁生長;形態(tài)特性：成纖維細(xì)胞;相關(guān)產(chǎn)品有：NCIH1651細(xì)胞、CAL 51細(xì)胞、NW-38細(xì)胞

HH [Human lymphoma] Cells;背景說明：詳見相關(guān)文獻(xiàn)介紹;傳代方法：每２-３天換液;生長特性：懸浮生長 ;形態(tài)特性：淋巴母細(xì)胞樣;相關(guān)產(chǎn)品有：C-4 I細(xì)胞、SW 1116細(xì)胞、H-345細(xì)胞

BayGenomics ES cell line RRO277 Cells(提供STR鑒定圖譜)

BayGenomics ES cell line YHB357 Cells(提供STR鑒定圖譜)

Ha1-4.37 Cells(提供STR鑒定圖譜)

PCRP-ARNT-2D11 Cells(提供STR鑒定圖譜)

B104 [Rat neuroblastoma] Cells(提供STR鑒定圖譜)

HPS0154 Cells(提供STR鑒定圖譜)

" "PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

PubMed=1873816

Isaacs W.B., Carter B.S., Ewing C.M.

Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.

Cancer Res. 51:4716-4720(1991)

PubMed=8104329; DOI=10.1002/pros.2990230206

Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P.

p53 oncogene mutations in three human prostate cancer cell lines.

Prostate 23:123-134(1993)

PubMed=8687134

Pandalai P.K., Pilat M.J., Yamazaki K., Naik H., Pienta K.J.

The effects of omega-3 and omega-6 fatty acids on in vitro prostate cancer growth.

Anticancer Res. 16:815-820(1996)

PubMed=9018337; DOI=10.1002/(SICI)1097-0045(19970101)30:1<58::AID-PROS9>3.0.CO;2-H

Webber M.M., Bello D., Quader S.T.A.

Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines.

Prostate 30:58-64(1997)

PubMed=9460501; DOI=10.1016/S0165-4608(97)00060-5

Nupponen N.N., Hyytinen E.-R., Kallioniemi A.H., Visakorpi T.

Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization.

Cancer Genet. Cytogenet. 101:53-57(1998)

PubMed=9823299

Khan J., Simon R.M., Bittner M., Chen Y.-D., Leighton S.B., Pohida T., Smith P.D., Jiang Y., Gooden G.C., Trent J.M., Meltzer P.S.

Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.

Cancer Res. 58:5009-5013(1998)

PubMed=10702678; DOI=10.1159/000015432

Pan Y., Kytola S., Farnebo F., Wang N., Lui W.-O., Nupponen N.N., Isola J.J., Visakorpi T., Bergerheim U.S.R., Larsson C.

Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping.

Cytogenet. Cell Genet. 87:225-232(1999)

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

PubMed=10754530; DOI=10.1002/(SICI)1097-0045(20000501)43:2<144::AID-PROS9>3.0.CO;2-H

Suzuki Y., Kondo Y., Himeno S., Nemoto K., Akimoto M., Imura N.

Role of antioxidant systems in human androgen-independent prostate cancer cells.

Prostate 43:144-149(2000)

PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H

Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.

Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines.

Mol. Carcinog. 28:236-246(2000)

PubMed=11135431; DOI=10.1002/1098-2264(2000)9999:9999<::AID-GCC1076>3.0.CO;2-E

Aurich-Costa J., Vannier A., Gregoire E., Nowak F., Cherif D.

IPM-FISH, a new M-FISH approach using IRS-PCR painting probes: application to the analysis of seven human prostate cell lines.

Genes Chromosomes Cancer 30:143-160(2001)

PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3

Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.

The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data.

Cancer Genet. Cytogenet. 124:112-121(2001)

PubMed=11304728; DOI=10.1002/pros.1045

van Bokhoven A., Varella-Garcia M., Korch C.T., Hessels D., Miller G.J.

Widely used prostate carcinoma cell lines share common origins.

Prostate 47:36-51(2001)

PubMed=11414198; DOI=10.1007/s004320000207

Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.-J.

Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.

J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=12606952; DOI=10.1038/sj.onc.1206247

Clark J., Edwards S., Feber A., Flohr P., John M., Giddings I., Crossland S., Stratton M.R., Wooster R., Campbell C., Cooper C.S.

Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays.

Oncogene 22:1247-1252(2003)

PubMed=12725112; DOI=10.1385/1-59259-372-0:21

Russell P.J., Kingsley E.A.

Human prostate cancer cell lines.

Methods Mol. Med. 81:21-39(2003)

PubMed=14518029; DOI=10.1002/pros.10290

van Bokhoven A., Varella-Garcia M., Korch C.T., Johannes W.U., Smith E.E., Miller H.L., Nordeen S.K., Miller G.J., Lucia M.S.

Molecular characterization of human prostate carcinoma cell lines.

Prostate 57:205-225(2003)

CLPUB00698

van Bokhoven A.

Models for prostate cancer. Molecular characterization and critical appraisal of human prostate carcinoma cell lines.

Thesis PhD (2004); Katholieke Universiteit Nijmegen; Nijmegen; Netherlands

PubMed=15486987; DOI=10.1002/pros.20158

Zhao H.-J., Kim Y., Wang P., Lapointe J., Tibshirani R., Pollack J.R., Brooks J.D.

Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.

Prostate 63:187-197(2005)

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Miroo T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

PubMed=17254797; DOI=10.1016/j.biologicals.2006.10.001

Azari S., Ahmadi N., Jeddi-Tehrani M., Shokri F.

Profiling and authentication of human cell lines using short tandem repeat (STR) loci: report from the National Cell Bank of Iran.

Biologicals 35:195-202(2007)

PubMed=17440963; DOI=10.1002/pros.20581

Takeda M., Mizokami A., Mamiya K., Li Y.-Q., Zhang J., Keller E.T., Namiki M.

The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.

Prostate 67:955-967(2007)

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

DOI=10.4172/2157-7145.S2-005

Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.R., Hart R.P., Furtado M.R.

STR profiling of human cell lines: challenges and possible solutions to the growing problem.

J. Forensic Res. 2 Suppl. 2:5-5(2011)

PubMed=21432867; DOI=10.1002/pros.21383; PMCID=PMC3426349

Tai S., Sun Y., Squires J.M., Zhang H., Oh W.K., Liang C.-Z., Huang J.-T.

PC3 is a cell line characteristic of prostatic small cell carcinoma.

Prostate 71:1668-1679(2011)

PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108

Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M.

Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.

Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011)

PubMed=22275356; DOI=10.1074/jbc.M111.302547; PMCID=PMC3322861

Lynch T.P., Ferrer C.M., Jackson S.R., Shahriari K.S., Vosseller K., Reginato M.J.

Critical role of O-linked beta-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis.

J. Biol. Chem. 287:11070-11081(2012)

PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017

Kong D.-X., Yamori T.

JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs.

Bioorg. Med. Chem. 20:1947-1951(2012)

PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511

Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.

Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.

PLoS ONE 7:E31628-E31628(2012)

PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665

Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T.

Identification of cancer cell-line origins using fluorescence image-based phenomic screening.

PLoS ONE 7:E32096-E32096(2012)

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189

Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Science 336:1040-1044(2012)

PubMed=23671654; DOI=10.1371/journal.pone.0063056; PMCID=PMC3646030

Lu Y.-H., Soong T.D., Elemento O.

A novel approach for characterizing microsatellite instability in cancer cells.

PLoS ONE 8:E63056-E63056(2013)

PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961

Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.

Cancer Res. 73:4372-4382(2013)

PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018

Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B.

Global proteome analysis of the NCI-60 cell line panel.

Cell Rep. 4:609-620(2013)

PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206

Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A.

The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.

Cancer Metab. 1:20.1-20.13(2013)

PubMed=24504141; DOI=10.3892/ijo.2014.2287; PMCID=PMC3977812

Suetens A., Moreels M., Quintens R., Chiriotti S., Tabury K., Michaux A., Gregoire V., Baatout S.

Carbon ion irradiation of the human prostate cancer cell line PC3: a whole genome microarray study.

Int. J. Oncol. 44:1056-1072(2014)

PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786

Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.

High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.

PLoS ONE 9:E92047-E92047(2014)

PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981

Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.

OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397

Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.

A resource for cell line authentication, annotation and quality control.

Nature 520:307-311(2015)

PubMed=26256267; DOI=10.1074/mcp.M115.047928; PMCID=PMC4597149

Shah P., Wang X.-C., Yang W.-M., Toghi Eshghi S., Sun S.-S., Hoti N., Chen L.-J., Yang S., Pasay J., Rubin A., Zhang H.

Integrated proteomic and glycoproteomic analyses of prostate cancer cells reveal glycoprotein alteration in protein abundance and glycosylation.

Mol. Cell. Proteomics 14:2753-2763(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878

Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Genome Med. 7:118.1-118.7(2015)

PubMed=26972028; DOI=10.1016/j.jprot.2016.03.008

Masuishi Y., Kimura Y., Arakawa N., Hirano H.

Identification of glycosylphosphatidylinositol-anchored proteins and omega-sites using TiO2-based affinity purification followed by hydrogen fluoride treatment.

J. Proteomics 139:77-83(2016)

PubMed=27141528; DOI=10.1016/j.dib.2016.04.001; PMCID=PMC4838930

Masuishi Y., Kimura Y., Arakawa N., Hirano H.

Data for identification of GPI-anchored peptides and omega-sites in cancer cell lines.

Data Brief 7:1302-1305(2016)

PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877

Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J.

Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.

Sci. Data 3:160052-160052(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Miroo T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121

Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.

A map of mobile DNA insertions in the NCI-60 human cancer cell panel.

Mob. DNA 7:20.1-20.11(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076

Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

PubMed=29194687; DOI=10.1002/pros.23459; PMCID=PMC5768451

Fiandalo M.V., Wilton J.H., Mantione K.M., Wrzosek C., Attwood K.M., Wu Y., Mohler J.L.

Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.

Prostate 78:213-221(2018)

PubMed=30244336; DOI=10.1007/s00345-018-2501-6

Samli H., Samli M., Vatansever B., Ardicli S., Aztopal N., Dincel D., Sahin A., Balci F.

Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.

World J. Urol. 37:1117-1126(2019)

PubMed=30787054; DOI=10.1158/1055-9965.EPI-18-1132; PMCID=PMC6548687

Hooker S.E. Jr., Woods-Burnham L., Bathina M., Lloyd S., Gorjala P., Mitra R., Nonn L., Kimbro K.S., Kittles R.A.

Genetic ancestry analysis reveals misclassification of commonly used cancer cell lines.

Cancer Epidemiol. Biomarkers Prev. 28:1003-1009(2019)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

PubMed=31404090; DOI=10.1371/journal.pone.0220807; PMCID=PMC6690527

Jeon J.M., Kwon O.K., Na A.-Y., Sung E.J., Cho I.J., Kim M., Yea S.S., Chun S.Y., Lee J.H., Ha Y.-S., Kwon T.G., Lee S.

Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells.

PLoS ONE 14:E0220807-E0220807(2019)"